Friday, March 4, 2016

Propanc Health Group Corp. (PPCH) Releases Study Results for Lead Product, Confirms Potential to Fight Certain Cancer Types

Propanc Health Group Corp. (OTCQB: PPCH) is an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients suffering from solid tumors, such as those resulting from pancreatic, ovarian, and colorectal cancers. The company recently announced results from studies for its lead product, PRP, confirming a synergistic response to a broad range of cancer indications, including kidney, melanoma, brain, prostate, liver, uterine and lung cancers. The data provides compelling evidence that PRP has the potential to fight a broad range of cancer types, some with significant unmet medical needs. The company will continue to investigate PRP’s efficacy in these indications through clinical trials.

Moreover, data from the recent cell line studies tested at the R&D facility of Propanc’s contract research partner, vivoPharm LLC, which is headquartered in Hershey, Pennsylvania, showed a synergistic response between the two active components, trypsinogen and chymotrypsinogen, further strengthening its lead patent claims in key jurisdictions throughout North America and Europe.

The company has also confirmed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, currently scheduled for the end of April. The purpose of the meeting is to discuss Propanc’s ongoing development activities for PRP, including preparation and structure of animal safety/toxicology studies and its proposed early stage patient trials, together with supporting activities.

Propanc has developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Its products involve or employ proenzymes, which are inactive precursors of enzymes.

Learn more by visiting www.propanc.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: